This article is more than 5 years old. Information may no longer be current.
OCT study will evaluate novel SES
Click Here to Manage Email Alerts
A new optical coherence tomography study is underway to evaluate performance of a sirolimus-eluting absorbable polymer coronary stent system compared with an everolimus-eluting coronary stent system, according to a press release issued by Micell Technologies.
The OCT study will compare changes in coronary arteries between 6 and 24 months following treatment with the MiStent sirolimus-eluting absorbable polymer stent system (Micell Technologies) or the Xience V everolimus-eluting stent system (Abbott Vascular). Enrollment of 60 patients has been completed, according to the release.
The OCT study is part of the larger DESSOLVE III study, a 1:1 randomized comparison of target lesion failure at 12 months for MiStent vs. Xience in 1,400 patients. Results of the DESSOLVE III trial are anticipated in the first quarter of 2017, according to the release.
The device features a bioabsorbable coating for rapid polymer dissolution while still allowing continuous drug delivery. MiStent SES has CE Mark in the European Union. EU approval was supported by data from the DESSOLVE I and II trials. It is not yet approved in the United States.